Clinical evidence of sesame (Sesamum indicum L.) products and its bioactive compounds on anthropometric measures, blood pressure, glycemic control, inflammatory biomarkers, lipid profile, and oxidative stress parameters in humans: a GRADE-assessed systematic review and dose-response meta-analysis.

Thirteen trials, with interventions ranging from 4 to 12 weeks and involving 521 participants, demonstrated significant reductions in glycated hemoglobin (HbA1c) (Standardized Mean Difference [SMD] = − 0.67; 95% Confidence Interval [CI] − 1.01, − 0.32; P < 0.001), C-reactive protein (CRP) (SMD = − 0.51; 95% CI − 0.96, − 0.05; P = 0.028), and interleukin-6 (IL-6) (SMD = − 0.74; 95% CI − 1.16, − 0.32; P < 0.001), and a marginally significant effect on fasting blood sugar (FBS) (SMD = − 0.57; 95% CI − 1.16, 0.02; P = 0.057).

also in 26,082 other papers